Company intelligence / Profile preview
Heptech
Rio de Janeiro, Rio de Janeiro, Brazilheptech.com.br ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Heptech has developed safer bovine heparin alternatives, including a safe bovine heparin (SBH) comparable to porcine heparin, a pharmacopeia-compliant bovine low molecular weight heparin (B-LMWH), and an innovative low anticoagulant heparin that reduces tumor growth and metastasis. The company is advancing these through scale-up, IP protection, and partnership development. No published human clinical results yet.
- Therapeutic areas
- OncologyCardiovascular
- Modalities
- Heparin-derived productsSulfated polysaccharides
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
FAPERJ – funding/grants partner for R&D scale-upSEBRAE – CATALISA ICT project participant for product development support
Beyond the preview
Go deeper on Heptech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Heptech.